Recombinant activated protein C: the key is clinical assessment of risk of death, not subset analysis
|
Descargar SCORM
Este recurso ha sido solicitado 1 veces (0 veces en los últimos 31 días).
Para poder solicitar este recurso debe identificarse como usuario de la biblioteca
|
| |
Ver
Detalles del recurso
|
|
|
Recombinant activated protein C: the key is clinical assessment of risk of death, not subset analysis
|
| Id. |
7960633 |
| Idioma |
inglés
|
| Titulo |
Recombinant activated protein C: the key is clinical assessment of risk of death, not subset analysis |
| Autor(es) |
Dellinger, R Phillip
|
| Localización |
http://www.pubmedcentral.gov/articlerender.fcgi?artid=1550791
|
| Versión |
1.0 |
| Estado |
Final
|
| Descripción |
The PROWESS (Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis) trial demonstrated a 6.1% absolute decrease in mortality with a p value of 0.005. Despite the impressive results of this trial, criticism of the study has targeted various aspects of design, analysis and interpretation. Additional studies of recombinant activated protein C (rhAPC) have added to our understanding about this drug and to controversy as well. So how do we deal with rhAPC use in our clinical practice?
|
| Palabras clave |
Commentary
|
| Tipo de recurso |
Text
|
| Tipo de Interactividad |
Expositivo
|
| Nivel de Interactividad |
muy bajo
|
| Audiencia |
Estudiante
Profesor
Autor
|
| Estructura |
Atomic |
| Coste |
no
|
| Copyright |
sí
|
| Requerimientos técnicos |
Browser: Any
|
| Fecha de contribución |
03-dic-2006 |
| Contacto |
|
|
|
|
|
Valoración de los usuarios
No hay ninguna valoración para este recurso. Sea el primero en
valorar este recurso.
|
|
|
|
